Home / Growth Plan – Subscription Terms & Conditions

Growth Plan – Subscription Terms & Conditions

Growth Plan – Subscription Terms & Conditions

By subscribing to the Growth Plan, you agree to the following plan-specific terms. These apply in addition to the MAI CDMO Legal Terms.

1. What’s included

With the Growth Plan you get:

  • A dedicated, branded CDMO profile visible to all visitors.
  • Leads submitted via your profile form are sent to you promptly after our anti-spam review.
  • Leads generated through other promotional activities (such as fairs and events) are also communicated to you with priority.
  • Priority support from an assigned Account Manager.
  • Performance reports with recommendations (delivered twice per year: January–May and September–December).
  • Access to pharma projects posted on the platform by pharmaceutical companies.
  • Network access: See which companies are registered and send them targeted inquiry forms.

Note: Access to the network and projects facilitates outreach but does not guarantee any response, lead volume, or awarded projects.

2. Subscription and pricing

The Growth Plan is €49.99 per month, billed annually at a total of €599.88 VAT not included.

3. Renewal

Available payment methods:

  • SEPA direct debit
  • Card Payment

The subscription automatically renews at the end of each term unless cancelled by the subscriber at least thirty (30) days in advance.

Fees may be updated upon prior notice. If the subscriber does not accept the revised fee, it may cancel the subscription before the effective date.

The subscriber shall be responsible for keeping its contact details up to date.

4. Expiry and downgrade

In the event of non-payment, a grace period of forty-eight (48) hours shall be granted. If payment is not received in the provider’s account within this period, the subscription will automatically switch to the Basic Plan, with reduced features. This clause is established pursuant to the freedom of contract recognized in the Spanish Commercial Code (arts. 1 et seq.) and Civil Code (art. 1,261), as well as Law 7/1998, of April 13, on General Conditions of Contracting, last updated 16/03/2019, ensuring clarity, precision, and transparency for the parties.

Industry News

Check out the latest trends in the contract manufacturing industry

How Biopharmaceutical CDMOs Optimize Cell Line Development & Process Yields
How Biopharmaceutical CDMOs Optimize Cell Line Development & Process Yields

2026-02-12

Beyond Capacity: How Smarter Science is Redefining Biologics Manufacturing

See more
Key Capabilities to Look for in a Contract Manufacturing Organization
Key Capabilities to Look for in a Contract Manufacturing Organization

2026-02-04

What truly matters when selecting a Contract Manufacturing Organization for clinical and commercial success

See more
Why Regulatory Experience Is Critical When Choosing a Veterinary CDMO
Why Regulatory Experience Is Critical When Choosing a Veterinary CDMO

2026-01-30

Regulatory expertise can be the difference between a smooth veterinary drug approval and costly delays.

See more

View all News

WORLD CLASS CONTRACT MANUFACTURERS

Leading CMOs and CDMOs

United States North America
 
Adare Pharma | US
Adare Pharma | US

Adare Pharma is a global CDMO with sites in US and EU providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets. Adare s proprietary technology platforms specialize in ODT s, taste masking and customized drug release.

Activity: FDF / DRUG PRODUCTS, SERVICES manufacturing

Uses: Human, Veterinary

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Compliance: ISO, EMA (EU GMP), FDA (cGMP), Health Canada...

Markets: DIGEMID (Peru), COFEPRIS (Mexico), INVIMA...

France Europe
 
Cenexi SAS
Cenexi SAS

Accueil Sites Osny. Acquired in 2011, the Osny site specializes in the development and production of highly active solid pharmaceutical forms (hormonal and allergens). This 4,000 m2 pharmaceutical plant located 36 km northwest of Paris employs around a hundred people.

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium

Compliance: EMA (EU GMP), FDA (cGMP), ANVISA (Brazil B-GMP),...

Markets: FDA (USA), EMA (EU), PMDA (Japan), MHRA (UK), NMPA...

Italy Europe
 
Content Group | Pomezia Plant
Content Group | Pomezia Plant

Tubilux Pharma: registered office; manufacturing facility

Activity: FDF / DRUG PRODUCTS, SERVICES manufacturing

Uses: Commercial (Phase IV), Human, Veterinary

Services: N/A

Batch Size / Reactor: Medium, Large

Compliance: EMA (EU GMP), FDA (cGMP), TGA (Australia GMP),...

Markets: FDA (USA), EMA (EU), TGA (Australia), ANVISA...

Germany Europe
 
Glatt Pharmaceutical Services GmbH Co. & KG
Glatt Pharmaceutical Services GmbH Co. & KG

Your cGMP-compliant CDMO for end-to-end services in the complex oral solids dosage forms field, based in Binzen Germany

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Development services, Manufacturing services,...

Batch Size / Reactor: Small, Medium, Large

Compliance: EMA (EU GMP), FDA (cGMP)

Markets: FDA (USA), EMA (EU)

Germany Europe
 
Green Phoenix Labs GmbH
Green Phoenix Labs GmbH

Cell Therapy company with excess Cleanroom capacity

Activity: FDF / DRUG PRODUCTS, BIOLOGICS, SERVICES manufacturing

Uses: Investigational, Commercial (Phase IV), Human

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium

Compliance: EMA (EU GMP)

Markets: EMA (EU)

Spain Europe
Join to view all
PHARMALOOP S.L. - a Salvat Company
FDF / DRUG PRODUCTS PARTICLE ENGINEERING in Europe

Fully integrated CDMO solutions for Blow-Fill-Seal (BFS), sterile multidose, non-sterile multi-dose, sachets, capsules and tablets.

Activity: FDF / DRUG PRODUCTS, PARTICLE ENGINEERING manufacturing

Uses: Commercial (Phase IV), Human

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Compliance: ISO, EMA (EU GMP), FDA (cGMP)

Markets: FDA (USA), EMA (EU)

Switzerland Europe
 
Ophtapharm, a Sentiss Company
Ophtapharm, a Sentiss Company

Ophtalmic and Otic - Solutions, suspensions, emulsions, ointments and gels - FDA Approved facility

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Compliance: ISO, EMA (EU GMP), FDA (cGMP), World Health...

Markets: FDA (USA), EMA (EU)

United Kingdom Europe
 
Seda Pharma Development Services
Seda Pharma Development Services

Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology.

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Human

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium

Compliance: ECOVADIS, MHRA (UK GMP)

Markets: DIGEMID (Peru), COFEPRIS (Mexico), INVIMA...

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

ADRAGOS PHARMA
Sylentis
CGAM
Grifols
Cambrex
ReigJofre